Semtech (SMTC) stock surged over 21% after reporting solid Q4 earnings, driven by strong sales across key segments and a drop in debt.
Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 12 and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback